Imeglimin

Research use only, not for human use.

Imeglimin (EMD 387008) is an orally available antidiabetic compound that enhances mitochondrial function, enhances insulin secretion, promotes β-cell proliferation and improves pancreatic β-cell survival in mice.

Imeglimin (EMD 387008) is an oral glucose-lowering agent. Imeglimin improves insulin sensitivity. Imeglimin also reduces reactive oxygen species (ROS) production, increases mitochondrial DNA and improves mitochondrial function.

Preincubation with Imeglimin (10?mM for 4?h or 100?μM for 24?h) fully prevents tert-butylhydroperoxide (tBH)-induced cell death.:Cell Viability Assay Cell Line:Human endothelial cells (HMEC-1) Concentration:100?μM and 10?mM Incubation Time:100?μM for 24?h, 10?mM for 4?hResult:Prevention of cell death.

Imeglimin (200 mg/kg b.i.d. by oral gavage during the last 6 weeks of HFHSD feeding) significantly decreases hyperglycemia, restores normal glucose tolerance, and improves insulin sensitivity.Animal Model:Male C57BL/6JOlaHsd mice (4 weeks old) Dosage:200 mg/kg Administration:Oral gavage; b.i.d.; 6 weeks Result:A slight decrease in body weight and food intake associated with some diarrhea was observed but only during the first few days of treatment.

——

Others

Other Targets

Mitochondrial Metabolism | ROS

——

——

775351-65-0

155.2

C6H13N5

>98% (HPLC)

——

Cl.C[C@@H]1N=C(N)NC(=N1)N(C)C

——

(-20℃)

With Ice Pack

≥ 2 years